The Detrimental Impact of Ultra-Processed Foods on the Human Gut Microbiome and Gut Barrier
- PMID: 40077728
- PMCID: PMC11901572
- DOI: 10.3390/nu17050859
The Detrimental Impact of Ultra-Processed Foods on the Human Gut Microbiome and Gut Barrier
Abstract
Ultra-processed foods (UPFs) have become a widely consumed food category in modern diets. However, their impact on gut health is raising increasing concerns. This review investigates how UPFs impact the gut microbiome and gut barrier, emphasizing gut dysbiosis and increased gut permeability. UPFs, characterized by a high content of synthetic additives and emulsifiers, and low fiber content, are associated with a decrease in microbial diversity, lower levels of beneficial bacteria like Akkermansia muciniphila and Faecalibacterium prausnitzii, and an increase in pro-inflammatory microorganisms. These alterations in the microbial community contribute to persistent inflammation, which is associated with various chronic disorders including metabolic syndrome, irritable bowel syndrome, type 2 diabetes, and colorectal cancer. In addition, UPFs may alter the gut-brain axis, potentially affecting cognitive function and mental health. Dietary modifications incorporating fiber, fermented foods, and probiotics can help mitigate the effects of UPFs. Furthermore, the public needs stricter regulations for banning UPFs, along with well-defined food labels. Further studies are necessary to elucidate the mechanisms connecting UPFs to gut dysbiosis and systemic illnesses, thereby informing evidence-based dietary guidelines.
Keywords: gut barrier; gut microbiome; ultra-processed foods (UPFs).
Conflict of interest statement
G.C. has received personal fees for acting as advisor for Ferring Therapeutics. A.G. reports personal fees for consultancy from Eisai Srl, 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, SinergieSrl, Board MRGE, and Sanofi SpA personal fees for acting as a speaker for Takeda SpA, AbbVie, and Sandoz SpA, and personal fees for acting on advisory boards for VSL3 and Eisai. G.I. has received personal fees for acting as speaker for Biocodex, Danone, Sofar, Malesci, Metagenics, and Tillotts Pharma, and for acting as consultant and/or advisor for Ferring Therapeutics, Giuliani, Malesci, and Tillotts Pharma. All other authors have no conflicts of interest to disclose.
Figures
References
-
- Cordova R., Viallon V., Fontvieille E., Peruchet-Noray L., Jansana A., Wagner K.H., Kyrø C., Tjønneland A., Katzke V., Bajracharya R., et al. Consumption of ultra-processed foods and risk of multimorbidity of cancer and cardiometabolic diseases: A multinational cohort study. Lancet Reg. Health Eur. 2023;35:100771. doi: 10.1016/j.lanepe.2023.100771. - DOI - PMC - PubMed
-
- Lane M.M., Davis J.A., Beattie S., Gómez-Donoso C., Loughman A., O’Neil A., Jacka F., Berk M., Page R., Marx W., et al. Ultra-processed food and chronic noncommunicable diseases: A systematic review and meta-analysis of 43 observational studies. Obes. Rev. 2021;22:e13146. doi: 10.1111/obr.13146. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
